160 related articles for article (PubMed ID: 37965304)
21. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
Xie J; Fan X; Su Y; Zhou H; Cao S; Zhu X; Zhu M; He C; Wang Y; Fan L; Ge Q; Zhu J; Liu B; Chen X; Xie Y; Ma L; Liu Y; Chen J; Wang H; Li Z
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1273-1283. PubMed ID: 35844038
[TBL] [Abstract][Full Text] [Related]
22. Anti-pan-neurofascin nodopathy: cause of fulminant neuropathy.
Acerra GM; Bevilacqua L; Noioso CM; Valle PD; Serio M; Vinciguerra C; Piscosquito G; Toriello A; Vegezzi E; Gastaldi M; Barone P; Iovino A
Neurol Sci; 2024 Apr; 45(4):1755-1759. PubMed ID: 38190082
[TBL] [Abstract][Full Text] [Related]
23. Tremor Associated with Chronic Inflammatory Demyelinating Polyneuropathy and Anti-Neurofascin-155 Antibodies.
Bailly L; Mongin M; Delorme C; Apartis E; Saheb S; Viala K; Roze E
Tremor Other Hyperkinet Mov (N Y); 2018; 8():606. PubMed ID: 30619643
[TBL] [Abstract][Full Text] [Related]
24. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
Kira JI
Front Neurol; 2021; 12():665136. PubMed ID: 34177770
[TBL] [Abstract][Full Text] [Related]
25. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.
Martinez-Martinez L; Lleixà MC; Boera-Carnicero G; Cortese A; Devaux J; Siles A; Rajabally Y; Martinez-Piñeiro A; Carvajal A; Pardo J; Delmont E; Attarian S; Diaz-Manera J; Callegari I; Marchioni E; Franciotta D; Benedetti L; Lauria G; de la Calle Martin O; Juárez C; Illa I; Querol L
J Neuroinflammation; 2017 Nov; 14(1):224. PubMed ID: 29145880
[TBL] [Abstract][Full Text] [Related]
26. Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.
Wang Z; Zhou X; Zhao N; Xie C; Zhu D; Guan Y
Neurol Sci; 2021 Jun; 42(6):2223-2233. PubMed ID: 33782779
[TBL] [Abstract][Full Text] [Related]
27. A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: Successfully treated with anti-CD20 monoclonal antibody.
Sokmen O; Demirci M; Tan E
Clin Neurol Neurosurg; 2021 Nov; 210():106961. PubMed ID: 34624826
[TBL] [Abstract][Full Text] [Related]
28. Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment.
Garg N; Park SB; Yiannikas C; Vucic S; Howells J; Noto YI; Mathey EK; Pollard JD; Kiernan MC
Muscle Nerve; 2018 May; 57(5):848-851. PubMed ID: 29130507
[TBL] [Abstract][Full Text] [Related]
29. Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy.
Afanasiev V; Tsouni P; Kuntzer T; Cairoli A; Delmont E; Vallat JM; Devaux J; Théaudin M
J Peripher Nerv Syst; 2024 Mar; 29(1):116-119. PubMed ID: 38123899
[TBL] [Abstract][Full Text] [Related]
30. Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese.
Wang W; Liu C; Li W; Zhang D; Shan Y; Zheng J; Shan J; Zhao Y; Yan C; Wang Q
Ann Clin Transl Neurol; 2022 May; 9(5):695-706. PubMed ID: 35313093
[TBL] [Abstract][Full Text] [Related]
31. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
Fan Y; Gao D; Zhang Z
Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
[TBL] [Abstract][Full Text] [Related]
32. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay.
Kadoya M; Kaida K; Koike H; Takazaki H; Ogata H; Moriguchi K; Shimizu J; Nagata E; Takizawa S; Chiba A; Yamasaki R; Kira JI; Sobue G; Ikewaki K
J Neuroimmunol; 2016 Dec; 301():16-22. PubMed ID: 27852440
[TBL] [Abstract][Full Text] [Related]
33. Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient.
Painous C; López-Pérez MÁ; Illa I; Querol L
Ann Clin Transl Neurol; 2018 Apr; 5(4):499-501. PubMed ID: 29687027
[TBL] [Abstract][Full Text] [Related]
34. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
[TBL] [Abstract][Full Text] [Related]
35. Telitacicept: First Approval.
Dhillon S
Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
[TBL] [Abstract][Full Text] [Related]
36. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
Fukami Y; Iijima M; Koike H; Yamada S; Hashizume A; Katsuno M
J Neurol; 2021 Oct; 268(10):3835-3844. PubMed ID: 33797627
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.
Broers MC; Wieske L; Erdag E; Gürlek C; Bunschoten C; van Doorn PA; Eftimov F; Kuitwaard K; de Vries JM; de Wit MY; Nagtzaam MM; Franken SC; Zhu L; Paunovic M; de Wit M; Schreurs MW; Lleixà C; Martín-Aguilar L; Pascual-Goñi E; Querol L; Jacobs BC; Huizinga R; Titulaer MJ
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):52-60. PubMed ID: 37879898
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy.
Dong M; Tai H; Yang S; Gao X; Pan H; Zhang Z
Clin Neurol Neurosurg; 2022 Dec; 223():107521. PubMed ID: 36401951
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders.
Chang SH; Wang J; Zhang X; Zhao N; Jia K; Yi M; Zhang QX; Zhai H; Li XW; Yang CS; Yang L; Zhang LJ
Clin Exp Immunol; 2021 Oct; 206(1):1-11. PubMed ID: 33998675
[TBL] [Abstract][Full Text] [Related]
40. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
Ma X; Fu X; Cui B; Lin H
Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
